Comparing the Clinical Characteristics of Male LADA, T1DM and T2DM Patients

Sponsor
Shanghai 10th People's Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04618354
Collaborator
(none)
632
1
24
26.4

Study Details

Study Description

Brief Summary

Diabetes is a common chronic disease in most parts of the world. Diabetes-related complications are harmful to the human body. Different types of diabetes have different levels of harm to the human body. There are also fewer studies on the relationship between specific types of diabetes and clinical diseases such as osteoporosis and Hypogonadism. Therefore, clarifying the differences in the clinical characteristics of adult men with late-onset autoimmune diabetes (LADA) ,Classical type 1 diabetes (T1DM) and type 2 diabetes (T2DM) will help to further understand the effects of diabetes on bone metabolism and sex hormones.

Condition or Disease Intervention/Treatment Phase
  • Other: No interventions

Detailed Description

Diabetes is a common chronic disease in most parts of the world. Diabetes-related complications are harmful to the human body. There are also fewer studies on the relationship between specific types of diabetes and clinical diseases such as osteoporosis and Hypogonadism. This study aimed to compare the prevalence of hypogonadism and osteoporosis among male patients with latent autoimmune diabetes (LADA), type 1 diabetes (T1DM) and type 2 diabetes (T2DM) and investigate the protective factors for hypogonadism and osteoporosis in these patients. This cross-sectional study evaluated male patients with LADA, T1DM, and T2DM who visited the endocrinology department of Shanghai Tenth People's Hospital for diabetes management. Sex hormones, lipid profiles, sex hormone-binding globulin (SHBG), glycosylated hemoglobin A1c, beta-cell function, uric acid, and osteocalcin were determined in serum samples. Therefor,clarifying the differences in the clinical characteristics of adult men with LADA, T1DM and T2DM will help to further understand the effects of diabetes on bone metabolism and sex hormones.

Study Design

Study Type:
Observational
Actual Enrollment :
632 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Comparing the Clinical Characteristics of Male Patients With Latent Autoimmune Diabetes ,Classic Type 2 Diabetes and Classic Type 2 Diabetes
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Nov 30, 2020
Actual Study Completion Date :
Dec 30, 2020

Arms and Interventions

Arm Intervention/Treatment
LADA group

The patient was diagnosed with late-onset autoimmune diabetes (LADA).

Other: No interventions
This clinical study is a retrospective study, and no interventions have been implemented for patients.

T2DM group

The patient was diagnosed with type 2 diabetes (T2DM).

Other: No interventions
This clinical study is a retrospective study, and no interventions have been implemented for patients.

T1DM group

The patient was diagnosed with type 1 diabetes (T1DM).

Other: No interventions
This clinical study is a retrospective study, and no interventions have been implemented for patients.

Outcome Measures

Primary Outcome Measures

  1. Testosterone [2016-2021]

    total testosterone (nmol/L), testosterone (nmol/L) and SHBG (nmol/L). Hypogonadism was defined as total testosterone levels less than 3.0 ng/ml

  2. Bone mineral density [2016-2021]

    Bone mineral density was measured at the lumbar spine, femoral neck, and right hip by dual-energy x-ray absorptiometry (DXA)

Secondary Outcome Measures

  1. HbA1c [2016-2021]

    Glycosylated hemoglobin A1c

  2. FBG [2016-2021]

    patients with fasting blood glucose 6.1mmol/l or more

  3. PBG [2016-2021]

    patients with 2 hour blood glucose 7.8mmol/l or more

  4. FINS [2016-2021]

    metabolic profile fasting insulin (IU/L)

  5. PINS [2016-2021]

    patients with 2 hour blood insulin

  6. TC [2016-2021]

    metabolic profile Total cholesterol (mmol/L)

  7. TG [2016-2021]

    metabolic profile Triglycerides (mmol/L)

  8. HDL-c [2016-2021]

    metabolic profile high-density lipoprotein cholesterol (mmol/L)

  9. LDL-c [2016-2021]

    metabolic profile Low-density lipoprotein cholesterol (mmol/L)

  10. FSH [2016-2021]

    follicle-stimulating hormone

  11. LH [2016-2021]

    luteinizing hormone

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 80 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. 30 ~ 80 years old male;

  2. Meet the American Diabetes Association (ADA) definition and standards for diabetes

Exclusion Criteria:
  1. having diseases that affect bone and calcium metabolism, such as hyperthyroidism, hyperparathyroidism, hypogonadism, cushing syndrome, rheumatoid arthritis, cirrhosis, or malignant tumor;

  2. the use in the past 6 months of drugs that interfere with bone and calcium metabolism, such as sex steroids, vitamin D metabolites, calcitonin, bisphosphonates, and thyroid hormone;

  3. moderate or severe liver and renal dysfunction, including serum alanine aminotransferase of 120 IU/L, aspartate aminotransferase of 80 IU/L, and serum creatinine of 120 μmol/L.

4)a history of congenital/hypogonadotropic hypogonadism or hyperthyroidism, or those who received testosterone replacement therapy in the past 6 months were excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Endocrinology, Shanghai Tenth People's Hospital Shanghai Shanghai China 200070

Sponsors and Collaborators

  • Shanghai 10th People's Hospital

Investigators

  • Study Chair: Shen Qu, Dr, Shang hai Tenth People's Hospital, Shanghai, Shanghai, China, 200072

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zhang Manna, Director, Principal Investigator, Clinical Professor, Shanghai 10th People's Hospital
ClinicalTrials.gov Identifier:
NCT04618354
Other Study ID Numbers:
  • LADA
First Posted:
Nov 5, 2020
Last Update Posted:
Jul 16, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 16, 2021